Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Image-guided drug delivery: preclinical applications and clinical translation.

Literature DB >> 26083469

Image-guided drug delivery: preclinical applications and clinical translation.

Tarun Ojha¹, Larissa Rizzo, Gert Storm, Fabian Kiessling, Twan Lammers.

Abstract

Image-guided drug delivery refers to the combination of drug targeting and imaging. Preclinically, image-guided drug delivery can be used for several different purposes, including for monitoring biodistribution, target site accumulation, off-target localization, drug release and drug efficacy. Clinically, it holds significant potential for preselecting patients. In this editorial, we briefly summarize the main principles of image-guided drug delivery, and we describe its potential for facilitating, furthering and personalizing nanomedicine treatments.

Entities: Chemical

Keywords: drug delivery; imaging; nanomedicine; theranostics

Mesh：

Year: 2015 PMID： 26083469 PMCID： PMC4529483 DOI： 10.1517/17425247.2015.1059420

Source DB: PubMed Journal: Expert Opin Drug Deliv ISSN： 1742-5247 Impact factor: 6.648

14 in total

Review 1. Impact of nanotechnology on drug delivery.

Authors: Omid C Farokhzad; Robert Langer
Journal: ACS Nano Date: 2009-01-27 Impact factor: 15.881

Review 2. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.

Authors: Jun Fang; Hideaki Nakamura; Hiroshi Maeda
Journal: Adv Drug Deliv Rev Date: 2010-05-02 Impact factor: 15.470

Review 3. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress.

Authors: Twan Lammers; Fabian Kiessling; Wim E Hennink; Gert Storm
Journal: J Control Release Date: 2011-09-16 Impact factor: 9.776

4. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas--rationale for combination with radiotherapy.

Authors: M I Koukourakis; S Koukouraki; A Giatromanolaki; S Kakolyris; V Georgoulias; A Velidaki; S Archimandritis; N N Karkavitsas
Journal: Acta Oncol Date: 2000 Impact factor: 4.089

5. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.

Authors: Uma Prabhakar; Hiroshi Maeda; Rakesh K Jain; Eva M Sevick-Muraca; William Zamboni; Omid C Farokhzad; Simon T Barry; Alberto Gabizon; Piotr Grodzinski; David C Blakey
Journal: Cancer Res Date: 2013-02-19 Impact factor: 12.701

6. Noninvasive optical imaging of nanomedicine biodistribution.

Authors: Sijumon Kunjachan; Felix Gremse; Benjamin Theek; Patrick Koczera; Robert Pola; Michal Pechar; Tomas Etrych; Karel Ulbrich; Gert Storm; Fabian Kiessling; Twan Lammers
Journal: ACS Nano Date: 2012-10-24 Impact factor: 15.881

7. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors: M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal: Ann Oncol Date: 2004-03 Impact factor: 32.976

Review 8. Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound.

Authors: Holger Grüll; Sander Langereis
Journal: J Control Release Date: 2012-05-05 Impact factor: 9.776

9. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Authors: D W Northfelt; B J Dezube; J A Thommes; B J Miller; M A Fischl; A Friedman-Kien; L D Kaplan; C Du Mond; R D Mamelok; D H Henry
Journal: J Clin Oncol Date: 1998-07 Impact factor: 44.544

Review 10. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications.

Authors: Larissa Y Rizzo; Benjamin Theek; Gert Storm; Fabian Kiessling; Twan Lammers
Journal: Curr Opin Biotechnol Date: 2013-04-09 Impact factor: 9.740

11 in total

Review 1. Applying nanomedicine in maladaptive inflammation and angiogenesis.

Authors: Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder
Journal: Adv Drug Deliv Rev Date: 2017-05-12 Impact factor: 15.470

2. Tailoring the lipid composition of nanoparticles modulates their cellular uptake and affects the viability of triple negative breast cancer cells.

Authors: Hanan Abumanhal-Masarweh; Dana da Silva; Maria Poley; Assaf Zinger; Evgenya Goldman; Nitzan Krinsky; Ron Kleiner; Gal Shenbach; Josh E Schroeder; Jeny Shklover; Janna Shainsky-Roitman; Avi Schroeder
Journal: J Control Release Date: 2019-06-22 Impact factor: 9.776

3. Sodium bicarbonate nanoparticles modulate the tumor pH and enhance the cellular uptake of doxorubicin.

Authors: Hanan Abumanhal-Masarweh; Lilach Koren; Assaf Zinger; Zvi Yaari; Nitzan Krinsky; Galoz Kaneti; Nitsan Dahan; Yael Lupu-Haber; Edith Suss-Toby; Esther Weiss-Messer; Michal Schlesinger-Laufer; Janna Shainsky-Roitman; Avi Schroeder
Journal: J Control Release Date: 2019-01-05 Impact factor: 9.776

Image-guided drug delivery: preclinical applications and clinical translation.

Review 1. Impact of nanotechnology on drug delivery.

Review 2. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.

Review 3. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress.

4. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas--rationale for combination with radiotherapy.

5. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.

6. Noninvasive optical imaging of nanomedicine biodistribution.

7. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Review 8. Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound.

9. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

Review 10. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications.

Review 1. Applying nanomedicine in maladaptive inflammation and angiogenesis.

2. Tailoring the lipid composition of nanoparticles modulates their cellular uptake and affects the viability of triple negative breast cancer cells.

3. Sodium bicarbonate nanoparticles modulate the tumor pH and enhance the cellular uptake of doxorubicin.

Review 4. Tumor-targeted nanomedicines for cancer theranostics.

Review 5. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors.

Review 6. Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects.

7. Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium.

Review 8. Imaging-assisted anticancer nanotherapy.

9. Sonoporation enhances liposome accumulation and penetration in tumors with low EPR.

Review 10. Imaging Nanomedicine-Based Drug Delivery: a Review of Clinical Studies.